|
HY-100216-10mg
|
MedChemexpress LLC
|
SPDP [CAS 68181-17-9]
|
|
|
|
|
HY-100216-100mg
|
MedChemexpress LLC
|
SPDP [CAS 68181-17-9]
|
|
|
|
|
HY-100216-200mg
|
MedChemexpress LLC
|
SPDP [CAS 68181-17-9]
|
|
|
|
|
HY-100216-5mg
|
MedChemexpress LLC
|
SPDP [CAS 68181-17-9]
|
|
|
|
|
HY-100216-50mg
|
MedChemexpress LLC
|
SPDP [CAS 68181-17-9]
|
|
|
|
|
HY-100216-500mg
|
MedChemexpress LLC
|
SPDP [CAS 68181-17-9]
|
|
|
|
|
HY-101982-10mg
|
MedChemexpress LLC
|
Lys-SMCC-DM1 [CAS 1281816-04-3]
|
|
Cancer-programmed cell death
|
|
|
HY-101982-5mg
|
MedChemexpress LLC
|
Lys-SMCC-DM1 [CAS 1281816-04-3]
|
|
Cancer-programmed cell death
|
|
|
HY-103614-1g
|
MedChemexpress LLC
|
Thalidomide-O-amido-C8-NH2 (TFA) [CAS 1950635-16-1]
|
|
|
|
|
HY-103614-100mg
|
MedChemexpress LLC
|
Thalidomide-O-amido-C8-NH2 (TFA) [CAS 1950635-16-1]
|
|
|
|
|
HY-103614-2g
|
MedChemexpress LLC
|
Thalidomide-O-amido-C8-NH2 (TFA) [CAS 1950635-16-1]
|
|
|
|
|
HY-103614-500mg
|
MedChemexpress LLC
|
Thalidomide-O-amido-C8-NH2 (TFA) [CAS 1950635-16-1]
|
|
|
|
|
HY-108379-2mg
|
MedChemexpress LLC
|
Boc-C2-Urea-bis(Boc)-C4-Urea-4-phenylacetic acid [CAS 1610413-97-2]
|
|
Cancer-programmed cell death
|
|
|
HY-108738-1mg
|
MedChemexpress LLC
|
Daclizumab [CAS 152923-56-3]
|
|
COVID-19-immunoregulation
|
|
|
HY-108738-10mg
|
MedChemexpress LLC
|
Daclizumab [CAS 152923-56-3]
|
|
COVID-19-immunoregulation
|
|
|
HY-108738-5mg
|
MedChemexpress LLC
|
Daclizumab [CAS 152923-56-3]
|
|
COVID-19-immunoregulation
|
|
|
HY-108810-1mg
|
MedChemexpress LLC
|
Canakinumab [CAS 914613-48-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-108810-5mg
|
MedChemexpress LLC
|
Canakinumab [CAS 914613-48-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-108852-1mg
|
MedChemexpress LLC
|
Basiliximab [CAS 179045-86-4]
|
|
COVID-19-immunoregulation
|
|
|
HY-108852-10mg
|
MedChemexpress LLC
|
Basiliximab [CAS 179045-86-4]
|
|
COVID-19-immunoregulation
|
|
|
HY-108852-5mg
|
MedChemexpress LLC
|
Basiliximab [CAS 179045-86-4]
|
|
COVID-19-immunoregulation
|
|
|
HY-109714-100mg
|
MedChemexpress LLC
|
3,4-Benzocoumarin [CAS 2005-10-9]
|
|
COVID-19-immunoregulation
|
|
|
HY-109714-50mg
|
MedChemexpress LLC
|
3,4-Benzocoumarin [CAS 2005-10-9]
|
|
COVID-19-immunoregulation
|
|
|
HY-112498-10mg
|
MedChemexpress LLC
|
Cy3 NHS ester [CAS 1393363-07-9]
|
|
|
|
|
HY-112498-25mg
|
MedChemexpress LLC
|
Cy3 NHS ester [CAS 1393363-07-9]
|
|
|
|
